Higher parent smartphone use was associated with slower vocabulary growth from ages 5 to 7 years in a prospective cohort study.
|Articles|December 1, 2003
Accident-prone child: Stress, temperament, or ADHD?
Q Parents of a 4 1/2-year-old boy in my practice are concerned because he takes too many risks. They report that he always seems to be doing something dangerous, which often results in injury.
Advertisement
Advertisement
Related to this article
FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.
Tallie Z. Baram, MD, talks about how adding a measure of childhood unpredictability to ACEs screening may help pediatricians identify children at risk for mental health problems.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
The FDA granted priority review to efzimfotase alfa for HPP in patients aged 2 years and older; a decision is expected in the first half of 2027.
Adolescent VALIANT subgroup data show pegcetacoplan cut proteinuria 75% vs placebo, supporting its expanded pediatric kidney indication.
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time AAV9 gene therapy, as the first treatment for pediatric MPS IIIA (Sanfilippo syndrome type A).
Aquestive resubmitted its NDA for dibutepinephrine sublingual film Anaphylm, citing new human factors and PK data addressing the FDA's CRL.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Updated AAP guidance changes iron deficiency screening and treatment in children
2
FDA grants priority review to efzimfotase alfa for hypophosphatasia in patients aged 2 years and older
3
FDA approves levacetylleucine as first treatment for ataxia in ataxia-telangiectasia
4
Pegcetacoplan reduces proteinuria, stabilizes kidney function in adolescents with C3G and IC-MPGN
5